(Methylsulfonyl) ethyl benzene isoindoline derivatives and their pharmaceutical uses
Provided are (methylsulfonyl)ethyl benzene isoindoline compounds, and pharmaceutically acceptable salts, solvates, or stereoisomers thereof. Methods of use and pharmaceutical compositions of these compounds are also disclosed.
1. A pharmaceutical composition comprising a compound of formula (I):
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein:
R 1 is glucuronide (“gluc”), or (cyclopropyl)-C(O)—, wherein the cyclopropyl may be substituted with one or more hydroxyl groups;
R 2 is hydrogen, methyl, or gluc;
R 3 is hydrogen, ethyl, or gluc; and
R 4 is hydrogen, hydroxyl, or —O-gluc;
with the proviso that when R 2 is methyl and R 3 is ethyl, then R 1 cannot be unsubstituted (cyclopropyl)-C(O).
2. The composition of claim 1 , wherein R 1 is (cyclopropyl)-C(O)—.
3. The composition of claim 1 , wherein R 2 is hydrogen.
4. The composition of claim 1 , wherein R 2 is methyl.
5. The composition of claim 1 , wherein R 2 is gluc.
6. The composition of claim 1 , wherein R 3 is hydrogen.
7. The composition of claim 1 , wherein R 3 is ethyl.
8. The composition of claim 1 , wherein R 4 is hydroxyl.
9. The composition of claim 1 , wherein R 4 is —O-gluc.
10. A pharmaceutical composition comprising a compound having the structure:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
11. The composition of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
12. A method of treating or managing a disease or disorder comprising administering to a patient a composition of claim 1 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the disease or disorder is cancer, pain, arthritis, Crohn's disease, 5q-deletion syndrome, sickle cell anemia, cachexia, adult respiratory distress syndrome, macular degeneration, Graft versus Host Reaction, chronic pulmonary inflammatory diseases, psoriatic arthritis, multiple sclerosis, systemic lupus erythromatosis, ENL in leprosy, psoriasis, fibrotic disease, oncogenic or cancerous conditions, asthma, chronic obstructive pulmonary disease, or atopic dermatitis.
13. A method of treating or managing a disease or disorder comprising administering to a patient a compound of claim 10 , or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, wherein the disease or disorder is cancer, pain, arthritis, Crohn's disease, 5q-deletion syndrome, sickle cell anemia, cachexia, adult respiratory distress syndrome, macular degeneration, Graft versus Host Reaction, chronic pulmonary inflammatory diseases, psoriatic arthritis, multiple sclerosis, systemic lupus erythromatosis, ENL in leprosy, psoriasis, fibrotic disease, oncogenic or cancerous conditions, asthma, chronic obstructive pulmonary disease, or atopic dermatitis.